



CODIGO : 173732
NOMBRE PACIENTE : EITHAN GAEL GONZALEZ TOBAR **SEXO :** MASCULINO
FECHA DE NACIMIENTO : 17/02/2026 **REGISTRO CIVIL:** 1,086,109,118
NOMBRE RESPONSABLE : KARELI YASMIN TOBAR TEPUD
DOC.IDENTIDAD DE LA MADRE : 1,004,538,722
FECHA TOMA DE MUESTRA : 11/06/2026 **TIPO DE MUESTRA :** TALÓN
FECHA DE IMPRESIÓN : 01/07/2026 **PESO :** 2555

TAMIZAJE NEONATAL

ANÁLISIS MUESTRA DE SANGRE

| | RESULTADO | VALORES DE REFERENCIA | INTERPRETACIÓN |
|----------------------|--------------|---|----------------|
| T.S.H Neonatal | 0.73 µU/l/mL | >= 6 µU/l/mL talón en prematuros >= 10 µU/l/mL talón >= 15 µU/l/mL cordón | Normal |
| Deficiencia de G6PDH | 5.80 U/gHb | < 2.6 U/gHb | Normal |

TÉCNICA: Fluoroimmunoensayo (Delfia).

Procesado en Colombia por PREGEN.

Hemoglobinopatías AF Ausencia de hemoglobinas anormales Normal

TÉCNICA: Cromatografía Líquida de Alto Rendimiento (HPLC).

Procesado en Colombia por PREGEN.

TAMIZAJE AMPLIADO

ESPECTROMETRIA DE MASAS EN TANDEM

Procesado en Archimedlife international medical laboratory. 1110 Vienna.

DESORDENES DE AMINOÁCIDOS

Citrulina, Metionina, Leucina, Isoleucina, Valina, Fenilalanina, Tirosina.

Ausencia de metabolitos anormales Normal

PERFIL DE ACILCARNITINAS

C16, C18, C18:1, C16OH, C18:1OH, C8, C10:1, C5, C5DC, C4, C14, C14:1, C50H, C3, C5:1

Ausencia de metabolitos anormales Normal

RESULTADOS NORMALES


Recuerde que estas son pruebas de tamizaje que solo indican la probabilidad de que el recién nacido tenga una de las enfermedades estudiadas por el programa y pueden requerir pruebas adicionales para la confirmación de algún diagnóstico. La sensibilidad de estas pruebas se reduce a medida que aumenta la edad del paciente, por esto es conveniente realizarlas dentro del primer mes de nacido.

REVISADO : EDUVILIA JOHANA GOMEZ **PROCESADO :** MARIA JOSE PINZON GARCIA **FECHA :**
Bacterióloga Bacterióloga
Reg. 40.936.003 Reg. 1.015.469.392 01/07/2026

LABORATORIO PREGEN
Carrera 15a No 106-42
BOGOTA

Batch 2179, Rack A, Plate 1, Well B04, 173732
[9C3CEFD15545131D] Jun 18, 2026 13:04:17 Pressure = 70 bar (70 to 72)

AF



| PEAK | RT | REL RT | % CONC | AREA | COMMENT |
|-------------|-------|--------|--------|--------|-------------------|
| 1 | 0.413 | F 0.49 | 2.5% | 11608 | |
| 2 | 0.492 | F 0.59 | 2.7% | 12712 | |
| 3 | 0.683 | F 0.82 | 2.5% | 11796 | |
| 4 | 0.843 | F 1.01 | 13.5% | 63021 | Consistent with F |
| 5 | 0.977 | F 1.17 | 5.2% | 24206 | 3 |
| 6 | 1.188 | A 1.00 | 73.6% | 343329 | A peak - REVIEW |
| Total Area: | | | | 466672 | |

- Codes:
- 1) Wide A peak
 - 2) Area of A peak < 80%
 - 3) Peak area greater than expected
 - 4) Peak after A2
 - 5) Alc > 10%
 - 6) HbF or variant present
 - 7) Total sample area too small/big
 - 8) A2 is not within normal range

Dr. MARIA JOSE PINZON GARCIA
RED COLOMBIANA DE MEDICINA GENETICA SAS - PREGEN
BOGOTA
CARRERA 15 A # 106 - 42
11001 BOGOTA
Colombia

Date of Report 29.06.2026
Sample Received 22.06.2026
Date of Sampling 02.06.2026
LAB-ID 262028136

Medical Report

| | | | |
|---------------|-----------------------------------|-----------|----------|
| Patient name | GONZALEZ TOBAR EITHAN GAEL | Sample-ID | A0341593 |
| Date of Birth | 17.02.2026 | Gender | M |

Indication: Newborn Screening

Method(s): Immunoassay, Tandem mass spectrometry from Dried Blood Spot. qPCR from Dried Blood Spot.

Results:

| Parameter | Value | Unit | Reference |
|--|----------|--------|-----------|
| Birth weight (g) | 2555 | g | - |
| 17-hydroxyprogesterone (17OHP) | <5.0 | nmol/L | < 90.0 |
| Thyroid-stimulating hormone (TSH) | 0.7 | μU/mL | < 15.0 |
| Biotinidase | 276.5 | U | > 51.0 |
| Galactose-1-P-uridyltransferase (GALT) | 7.5 | U/g Hb | > 2.5 |
| Immunoreactive trypsinogen (IRT) | 15.3 | ng/mL | < 65.0 |
| Phenylalanine | 29.0 | μmol/L | < 150.0 |
| Amino acid profile | negative | | - |
| Acylcarnitine profile | negative | | - |

Interpretation: NEGATIVE RESULT

| | |
|---------------|-----------------------------------|
| Patient name | GONZALEZ TOBAR EITHAN GAEL |
| Date of Birth | 17.02.2026 |

| | |
|-----------|----------|
| Sample-ID | A0341593 |
| Gender | M |

Results:

| Parameter | Value | Unit | Reference |
|--|-------|--------|---------------|
| Phenylalanine (Phe) | 29.0 | µmol/L | < 150.0 |
| Phenylalanine / Tyrosine ratio (Phe/Tyr) | 0.29 | µmol/L | < 2.20 |
| Tyrosine (Tyr) | 101.3 | µmol/L | < 200.0 |
| Leucine (Leu) | 93.5 | µmol/L | < 270.0 |
| Valine (Val) | 54.4 | µmol/L | < 200.0 |
| Methionine (MET) | 20.1 | µmol/L | < 78.0 |
| Methionine / Phenylalanine (Met/Phe) | 0.69 | µmol/L | < 1.60 |
| Citrulline (Cit) | 14.1 | µmol/L | < 50.0 |
| Ornithine (Orn) | 102.9 | µmol/L | < 250.0 |
| Ornithine / Citrulline ratio (Orn/Cit) | 7.30 | µmol/L | 1.50 - 20.00 |
| Proline (Pro) | 144.2 | µmol/L | < 350.0 |
| Alanine (Ala) | 136.2 | µmol/L | < 750.0 |
| Arginine (Arg) | 46.7 | µmol/L | < 100.0 |
| Aspartic acid (Asp) | 74.0 | µmol/L | < 100.0 |
| Glutamic acid (Glu) | 249.5 | µmol/L | < 600.0 |
| Glycamine (Gly) | 195.6 | µmol/L | < 700.0 |
| Free carnitine (C0) | 23.78 | µmol/L | 6.00 - 100.00 |
| acetylcarnitine (C2) | 7.22 | µmol/L | 1.34 - 48.81 |
| propionylcarnitine (C3) | 1.10 | µmol/L | 0.13 - 6.60 |
| butyryl-/isobutyrylcarnitine (C4) | 0.13 | µmol/L | 0.03 - 0.90 |
| isovaleryl-/2-methylbutyrylcarnitine(C5) | 0.11 | µmol/L | 0.02 - 2.00 |
| tiglylcarnitine (C5:1) | 0.01 | µmol/L | < 0.20 |
| hydroxyvalerylcarnitine (C5OH) | 0.31 | µmol/L | 0.02 - 0.57 |
| glutaryl carnitine (C5DC) | 0.05 | µmol/L | < 0.30 |
| hexanoylcarnitine (C6) | 0.07 | µmol/L | 0.01 - 0.13 |
| octanoylcarnitine (C8) | 0.06 | µmol/L | 0.01 - 0.30 |
| decanoylcarnitine (C10) | 0.04 | µmol/L | 0.01 - 0.36 |
| decenoylcarnitine (C10:1) | 0.12 | µmol/L | < 0.30 |
| dodecanoylcarnitine (C12) | 0.09 | µmol/L | 0.10 - 0.60 |
| myristoylcarnitine (C14) | 0.25 | µmol/L | 0.01 - 0.57 |
| tetradecenoylcarnitine (C14:1) | 0.13 | µmol/L | 0.10 - 0.43 |
| palmitoylcarnitine (C16) | 1.16 | µmol/L | 0.62 - 7.81 |
| 3-hydroxypalmitoylcarnitine (C16OH) | 0.04 | µmol/L | < 0.10 |
| stearoylcarnitine (C18) | 0.59 | µmol/L | 0.30 - 2.40 |
| oleyl carnitine (C18:1) | 3.16 | µmol/L | 0.06 - 3.86 |
| 3-hydroxystearoylcarnitine (C18OH) | 0.01 | µmol/L | < 0.09 |
| malonylcarnitine (C3DC) | 0.07 | µmol/L | < 0.50 |

Please note: Inconspicuous negative biochemical results cannot exclude any inborn error of metabolism or endocrine disorder with certainty in newborns. We recommend any follow-up or genetic testing if any clinical symptoms are present.

Authorized By: Assoc.-Prof. Dr. Andrea-Romana KASPER, MD, PhD
[Specialist for Pediatrics, Neonatology and Nutrition]

Report was electronically signed and approved.